In plain language
Cerebrolysin is a mixture of small peptides and amino acids derived from pig brain tissue, given by injection. It is approved in several countries for stroke and dementia, but large independent reviews have found the evidence mixed and often low quality.
What it is explored for
Cerebrolysin is approved in several countries and has a long history of clinical use for brain-related conditions, which sets it apart from purely research-stage compounds. In fairness, independent reviews (including Cochrane analyses) have generally found the human evidence mixed and of low certainty. Here is where it is most studied and used.
- Stroke recovery research
- Dementia and cognition research
- Traumatic brain injury research
- Neuroprotection and repair
- Neuroplasticity support research
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.
How it works
Cerebrolysin is not a single molecule but a standardized mixture of low-molecular-weight peptides and free amino acids. It is proposed to act like a neurotrophic agent.
- Neurotrophic-like activity. Proposed to mimic the action of nerve growth factors, supporting neuronal survival in preclinical models.
- Neuroprotection. Associated in animal studies with reduced excitotoxicity and protection of neurons after injury.
- Synaptic and repair support. Reported to influence neuroplasticity and repair processes following brain injury in preclinical work.
Because the product is a complex mixture, precise mechanisms are hard to pin down and are based largely on preclinical models.
Evidence summary
Cerebrolysin has been studied in stroke, dementia, and traumatic brain injury, and is approved in some countries. However, independent systematic reviews (including Cochrane analyses) have generally found the evidence inconclusive or of low certainty, with concerns about trial quality. Results are mixed and contested.
Reported safety & side effects
In clinical use Cerebrolysin is generally described as well-tolerated, with mostly mild side effects reported. As an injectable biological mixture, it carries the usual risks of injection, and long-term independent safety data is limited.
Frequently asked
Is Cerebrolysin FDA-approved?
No. Cerebrolysin is approved in several countries but is not approved by the FDA and is not available as an approved medicine in the United States.
Does it work for dementia or stroke?
The evidence is mixed. Some trials report benefits, but independent reviews have found the overall evidence inconclusive or of low quality, so firm conclusions cannot be drawn.